SCHEMBL4668620

SCHEMBL4668620

COCNC(=O)c1ccc2c(c1)N=C(Cl)c1ccccc1S2

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.60
NPSR1 Q6W5P4 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
CNR1 P21554 7/20 0.56
CNR2 P34972 2/20 0.56
KDM4E B2RXH2 1/20 0.54
POLB P06746 1/20 0.53
MAPT P10636 3/20 0.53
ALDH1A1 P00352 2/20 0.52
PLA2G1B P04054 1/20 0.52
HTT P42858 1/20 0.52
PAX8 Q06710 1/20 0.52
ATG4B Q9Y4P1 1/20 0.52
GAA P10253 1/20 0.52
LMNA P02545 1/20 0.51
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13808239 0.90 TP53 (0.73) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL13808126 0.86 TP53 (0.75) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL13807802 0.85 TP53 (0.53) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL5057296 0.85 CNR1 (0.72) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL4670768 0.84 PLEC (0.53) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL4748210 0.84 CNR1 (0.78) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL5064837 0.83 POLB (0.71) TP53SMN1; SMN2CNR1CNR2POLB
SCHEMBL5057539 0.83 CNR1 (0.60) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL13807812 0.83 MAPT (0.68) TP53NPSR1SMN1; SMN2CNR1CNR2
SCHEMBL13808127 0.83 TP53 (0.64) TP53NPSR1SMN1; SMN2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008118141-A2 USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY ACADIA PHARMACEUTICALS INC. (US) 2008-10-02 WO disclosed
EP-1937614-A1 IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES Arcadia Pharmaceuticals Inc. (US) 2008-07-02 EP disclosed
EP-1937677-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE Arcadia Pharmaceuticals Inc. (US) 2008-07-02 EP disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed
US-20070106074-A1 Iron catalyzed cross-coupling reactions of imidoyl derivatives ACADIA PHARMACEUTICALS 2007-05-10 US disclosed
US-20070105819-A1 CB-1 modulating compounds and their use ACADIA PHARMACEUTICALS, INC. 2007-05-10 US disclosed
WO-2007047737-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2007-04-26 WO disclosed
WO-2007047776-A1 IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES ACADIA PHARMACEUTICALS INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070106074-A1 Iron catalyzed cross-coupling reactions of imidoyl derivatives SDHB, TFRC, SLC40A1 TP53 4530/4885NPSR1 3653/4885SMN1; SMN2 3851/4885
US-20070105819-A1 CB-1 modulating compounds and their use CNR1, CNR2, FAAH TP53 4870/4885NPSR1 72/4885SMN1; SMN2 2143/4885
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH TP53 4870/4885NPSR1 72/4885SMN1; SMN2 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.